Molecule Details
| InChIKey | UIQMVEYFGZJHCZ-SSTWWWIQSA-N |
|---|---|
| Compound Name | Nalorphine |
| Canonical SMILES | C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 4 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 8.0 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB11490 |
|---|---|
| Drug Name | Nalorphine |
| CAS Number | 62-67-9 |
| Groups | experimental vet_approved |
| ATC Codes | V03AB02 |
| Description | Nalorphine is a mixed opioid agonist–antagonist. It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics. It is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to dete... |
Categories: Alkaloids Antidotes Central Nervous System Agents Heterocyclic Compounds, Fused-Ring Mixed Agonist / Antagonist Opioids Morphinans Opiate Alkaloids Opioid Antagonists Opioids Peripheral Nervous System Agents Phenanthrenes Semi-synthetic Opioids Sensory System Agents
Cross-references: BindingDB: 50367061 ChEBI: 7458 CHEMBL415284 ChemSpider: 4447643 C11787 D08247 Wikipedia: Nalorphine ZINC: ZINC000003875420
Target Activities (4)
| Target | Gene | Organism | Category | Pfam | pChEMBL | Type | Source |
|---|---|---|---|---|---|---|---|
| P35372 | OPRM1 | Homo sapiens | Human | PF00001 | 9.4 | Ki | ChEMBL;BindingDB |
| P41145 | OPRK1 | Homo sapiens | Human | PF00001 | 8.7 | Ki | ChEMBL;BindingDB |
| P41143 | OPRD1 | Homo sapiens | Human | PF00001 | 7.2 | IC50 | ChEMBL;BindingDB |
| Q99720 | SIGMAR1 | Homo sapiens | Human | PF04622 | 6.6 | IC50 | ChEMBL;BindingDB |
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P41145 | OPRK1 | Kappa-type opioid receptor | agonist | targets |